



"Biomarkers" in medical imaging are the key to detecting and treating cancer

**MEDIAN Technologies names Ciaran Cooper
as Head of Business Development, Clinical Trials Imaging, North America**

Ciaran Cooper will be responsible for developing the company's US market in oncology clinical trials and will assist in managing the relationship between MEDIAN and Quintiles

Sophia Antipolis, France, April 4th 2012 – MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer, and a service provider for image interpretation and management in oncology clinical trials, announced today that it has named Ciaran Cooper as Head of Business Development, Clinical Trials Imaging, North America. Ciaran Cooper will be responsible for developing the company's US market in oncology clinical trials and will assist in managing the strategic relationship between MEDIAN Technologies and Quintiles.

Ciaran Cooper, an entrepreneur and early innovator in the clinical trials imaging services industry, brings over 20 years' experience in medical imaging with an emphasis in business development, strategic planning, and team management. Along with colleagues from the University of Chicago, Ciaran Cooper co-founded MIICRO, Inc. in 1995, the first imaging CRO specialized in early phase translational imaging with FDG PET. He was CEO of MIICRO until 2003. Since then, Ciaran Cooper has worked for several imaging services and technology companies as a senior manager in business development and thus brings with him a vast knowledge of various business models, therapeutic areas, and growth strategies.

"I'm very excited to join MEDIAN at this time in their development," said Ciaran Cooper. "MEDIAN's LMS solution provides a quantum leap forward in how medical imaging can be applied to oncology clinical trials. I look forward to carrying our message to market."

"We're thrilled to welcome Ciaran to our team," said Jerome Windsor, VP Business Development at MEDIAN Technologies. "Ciaran has a unique perspective on the industry and he brings an entrepreneurial spirit and enthusiasm that will fit well with our growing company."



MEDIAN

“Biomarkers” in medical imaging are the key to detecting and treating cancer

ALMDT
LISTED
NYSE
ALTERNEXT

About MEDIAN Technologies: MEDIAN Technologies provides advanced imaging solutions for diagnosing and monitoring cancer patients in clinical trials and in routine clinical practice. MEDIAN collaborates with institutes at the cutting edge of medical imaging, including the French National Institute for Computer Science and Control (INRIA), the University of Chicago, and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL). MEDIAN is present in the market through direct and indirect sales of its LMS solutions and through alliances with specialist cancer centers in Europe and the USA. MEDIAN has a strategic partnership with Quintiles, to offer integrated imaging services for clinical trials to customers worldwide.

Based in Sophia Antipolis, France, MEDIAN was founded in 2002 by Fredrik Brag (Current CEO), Gérard Milhiet, and Arnaud Butzbach. The company has a staff of 40, over half of whom work in R&D, and has a US-based subsidiary.

For more information on MEDIAN, please visit: www.mediantechologies.com

Contacts

MEDIAN Technologies

Fredrik Brag, CEO

+33 4 92 90 65 82

fredrik.brag@mediantechnologies.com

Press - ALIZE RP

Caroline Carmagnol

+ 33 6 64 18 99 59 // + 33 1 42 68 86 43

caroline@alizerp.com

Anne-Sophie Cosquéric

+ 33 1 42 68 86 41

Anne-sophie@alizerp.com